Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Metabolism of amitriptyline in patients with chronic renal failure.

Literature DB >> 6723762

Metabolism of amitriptyline in patients with chronic renal failure.

M Sandoz, S Vandel, B Vandel, B Bonin, B Hory, Y St Hillier, R Volmat.

Abstract

The metabolism of amitriptyline (AMT) has been studied in two groups of depressed in-patients on long term AMT therapy: 11 patients with no other major disease and 8 patients with chronic renal failure, who were being dialysed. The patients with renal insufficiency had decreased concentrations of AMT, nortriptyline (NT) and their unconjugated hydroxymetabolites compared to patients with normal kidney function. The plasma levels of conjugated products were extremely high in the uraemics. The latter metabolites are probably inert. The reduced concentration of unconjugated hydroxymetabolites , which are active compounds, may decrease the clinical effectiveness of the drug.

Entities: Chemical Disease Species

Mesh：

Substances：
Amitriptyline

Year: 1984 PMID： 6723762 DOI： 10.1007/BF00630290

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

56 in total

Review 1. Diseases and drug protein binding.

Authors: J P Tillement; F Lhoste; J F Giudicelli
Journal: Clin Pharmacokinet Date: 1978 Mar-Apr Impact factor: 6.447

2. Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline.

Authors: S Vandel; B Vandel; M Sandoz; G Allers; P Bechtel; R Volmat
Journal: Eur J Clin Pharmacol Date: 1978-11-27 Impact factor: 2.953

3. Prevalence of chronic renal failure and access to dialysis.

Authors: M McCormick; V Navarro
Journal: Int J Epidemiol Date: 1973 Impact factor: 7.196

4. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors: M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal: N Engl J Med Date: 1971-07-29 Impact factor: 91.245

5. Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man.

Authors: L F Gram; K Overo; L Kirk
Journal: Am J Psychiatry Date: 1974-08 Impact factor: 18.112

6. Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.

Authors: I Odar-Cederlöf; O Borgå
Journal: Eur J Clin Pharmacol Date: 1974 Impact factor: 2.953

7. Lithocholate cholestasis--sulfated glycolithocholate-induced intrahepatic cholestasis in rats.

Authors: I M Yousef; B Tuchweber; R J Vonk; D Massé; M Audet; C C Roy
Journal: Gastroenterology Date: 1981-02 Impact factor: 22.682

8. Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity.

Authors: W Z Potter; H M Calil; A A Manian; A P Zavadil; F K Goodwin
Journal: Biol Psychiatry Date: 1979-08 Impact factor: 13.382

9. Determination of amitriptyline and its major basic metabolites in human urine by high-performance liquid chromatography.

Authors: S R Biggs; L F Chasseaud; D R Hawkins; I Midgley
Journal: Drug Metab Dispos Date: 1979 Jul-Aug Impact factor: 3.922

10. Urinary excretion of D-glucaric acid, an indicator of drug metabolizing enzyme activity, in patients with impaired renal function.

Authors: D Kampf; I Roots; A G Hildebrandt
Journal: Eur J Clin Pharmacol Date: 1980-10 Impact factor: 2.953

7 in total

Metabolism of amitriptyline in patients with chronic renal failure.

Review 1. Diseases and drug protein binding.

2. Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline.

3. Prevalence of chronic renal failure and access to dialysis.

4. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

5. Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man.

6. Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.

7. Lithocholate cholestasis--sulfated glycolithocholate-induced intrahepatic cholestasis in rats.

8. Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity.

9. Determination of amitriptyline and its major basic metabolites in human urine by high-performance liquid chromatography.

10. Urinary excretion of D-glucaric acid, an indicator of drug metabolizing enzyme activity, in patients with impaired renal function.

Review 1. Guide to drug dosage in renal failure.

2. Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure.

Review 3. Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Review 4. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

5. Neuropsychiatric manifestation after a stroke: newly developed symptoms or side-effect of drug?

Review 6. Clinical pharmacokinetic considerations in the elderly. An update.

7. Pain management in patients with chronic kidney disease and end-stage kidney disease.